Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 12.9 CAD 0.78% Market Closed
Market Cap: 148.1m CAD

Intrinsic Value

The intrinsic value of one RX stock under the Base Case scenario is 13.09 CAD. Compared to the current market price of 12.9 CAD, Biosyent Inc is Undervalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RX Intrinsic Value
13.09 CAD
Undervaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Biosyent Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about RX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is RX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Biosyent Inc.

Explain Valuation
Compare RX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about RX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biosyent Inc

Current Assets 36m
Cash & Short-Term Investments 23.4m
Receivables 6.3m
Other Current Assets 6.2m
Non-Current Assets 11.8m
Long-Term Investments 5.4m
PP&E 1m
Intangibles 4.9m
Other Non-Current Assets 426.4k
Current Liabilities 7.1m
Accounts Payable 6.4m
Other Current Liabilities 700k
Non-Current Liabilities 775.8k
Long-Term Debt 681.3k
Other Non-Current Liabilities 94.5k
Efficiency

Free Cash Flow Analysis
Biosyent Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Biosyent Inc

Revenue
42.2m CAD
Cost of Revenue
-9.5m CAD
Gross Profit
32.7m CAD
Operating Expenses
-21.8m CAD
Operating Income
10.9m CAD
Other Expenses
-2.2m CAD
Net Income
8.6m CAD
Fundamental Scores

RX Profitability Score
Profitability Due Diligence

Biosyent Inc's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional ROIC
Exceptional Gross Margin
Positive 3Y Average ROE
67/100
Profitability
Score

Biosyent Inc's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

RX Solvency Score
Solvency Due Diligence

Biosyent Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Biosyent Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RX Price Targets Summary
Biosyent Inc

Wall Street analysts forecast RX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RX is 13.77 CAD with a low forecast of 13.64 CAD and a high forecast of 14.18 CAD.

Lowest
Price Target
13.64 CAD
6% Upside
Average
Price Target
13.77 CAD
7% Upside
Highest
Price Target
14.18 CAD
10% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for RX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one RX stock?

The intrinsic value of one RX stock under the Base Case scenario is 13.09 CAD.

Is RX stock undervalued or overvalued?

Compared to the current market price of 12.9 CAD, Biosyent Inc is Undervalued by 1%.

Back to Top